(Q34529943)

English

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

Europe PubMed Central

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

systematic review

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Sandborn WJ

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Hanauer SB

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

0 references

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

29-42

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Review article: balsalazide therapy in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

An oral preparation to release drugs in the human colon

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

Low albumin gradient ascites complicating severe pseudomembranous colitis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01408.X

21 January 2018

Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/citations/10.2165/00003495-199957030-00013

Identifiers

10.1046/J.1365-2036.2003.01408.X

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34529943&oldid=2143263061"